Lv2
180 积分 2022-04-24 加入
Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms
11天前
已完结
Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias
1个月前
已完结
Chronic myelomonocytic leukemia treated with 5-azacytidine – results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system
3个月前
已完结
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors
6个月前
已完结
Treating acute myelogenous leukemia in patients aged 70 and above: Recommendations from the International Society of Geriatric Oncology (SIOG)
6个月前
已完结
AML treatment: conventional chemotherapy and emerging novel agents
6个月前
已完结
Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation
7个月前
已完结
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
7个月前
已完结
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
7个月前
已完结
Understanding differential technologies for detection of MRD and how to incorporate into clinical practice
7个月前
已关闭
皖公网安备34019202002308
